These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2168142)

  • 1. Mechanism of action of lomefloxacin.
    Piddock LJ; Hall MC; Wise R
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1088-93. PubMed ID: 2168142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
    Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):656-62. PubMed ID: 3164987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA; Shatzer KL; Venezio FR
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.
    Stratton CW; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):29S-34S. PubMed ID: 2791495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of lomefloxacin (NY-198 or SC 47111).
    Shah PM; Müller S; Kipp J; Stille W
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):97S-101S. PubMed ID: 2791506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of Q-35, a new fluoroquinolone.
    Ito T; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1708-14. PubMed ID: 1329626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa.
    Rossolini GM; Valentini S; Satta G
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):57S-64S. PubMed ID: 2507221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.
    Molinari G; Bandelloni R; Paglia P; Debbia E; Schito GC
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):53S-56S. PubMed ID: 2791499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial and plasmid curing activity of lomefloxacin in vitro.
    Derlot E; Poyart-Salmeron C; Courvalin P
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1048-52. PubMed ID: 2515963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.
    Pruul H; McDonald PJ
    J Antimicrob Chemother; 1990 Jan; 25(1):91-101. PubMed ID: 2108116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK; Nisha AK; Bhattacharya SS; Ramamoorthy U; Lal HM
    Indian J Med Res; 1990 May; 91():182-4. PubMed ID: 2397938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.